E2 ModerateModerate confidencePEM not requiredCase-ControlPeer-reviewedMachine draft
The Impact of Micro RNA-320a Serum Level on Severity of Symptoms and Cerebral Processing of Pain in Patients with Fibromyalgia.
Hussein, Mona, Fathy, Wael, Abdelaleem, Enas A et al. · Pain medicine (Malden, Mass.) · 2022 · DOI
Quick Summary
Researchers measured a molecule called miR-320a in the blood of people with fibromyalgia and compared it to healthy people. They found that fibromyalgia patients had higher levels of this molecule, and those with higher levels tended to have worse symptoms like pain, fatigue, sleep problems, and depression. However, this molecule did not appear to affect how the brain processes pain signals.
Why It Matters
This study identifies miR-320a as a potential blood biomarker associated with fibromyalgia symptom severity, which overlaps clinically with ME/CFS in fatigue and multisystem complaints. Understanding molecular mechanisms linking microRNAs to symptom burden could inform both conditions' pathophysiology and potentially guide future diagnostic or therapeutic strategies, especially given the frequent comorbidity of fibromyalgia and ME/CFS.
Observed Findings
- Fibromyalgia patients had significantly higher serum miR-320a levels compared to healthy controls (0.907 ± 0.022 vs 0.874 ± 0.015, p<0.001).
- miR-320a levels were significantly elevated in fibromyalgia patients with comorbid insomnia, chronic fatigue syndrome, persistent depressive disorder, and primary headache disorder.
- Positive correlations were found between miR-320a levels and disease duration (p<0.001), FIQR symptom severity scores (p=0.003), and NPSI neuropathic pain scores (p=0.002).
- No statistically significant correlations were detected between miR-320a levels and middle latency SSEP parameters (peak latencies and amplitudes).
Inferred Conclusions
- miR-320a is upregulated in fibromyalgia and may serve as a biomarker for disease presence and symptom severity.
- miR-320a levels have a functional relationship to symptom burden but not to objective neurophysiological measures of central pain processing.
- The association of miR-320a with multiple comorbidities suggests it may reflect a broader systemic inflammatory or metabolic perturbation in fibromyalgia.
Remaining Questions
- What is the mechanistic role of miR-320a in generating or amplifying fibromyalgia symptoms if it does not directly correlate with central pain processing?
- Is miR-320a elevation specific to fibromyalgia or does it occur in other chronic pain or fatigue conditions, including ME/CFS?
What This Study Does Not Prove
This study does not establish that miR-320a causes fibromyalgia symptoms—only that levels correlate with severity. The lack of association with objective neurophysiological markers (SSEPs) suggests miR-320a may reflect symptom reporting or peripheral inflammation rather than central pain processing mechanisms. Additionally, findings in fibromyalgia may not directly apply to ME/CFS without separate validation.
Tags
Symptom:Unrefreshing SleepPainFatigue
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:Small SampleMixed Cohort
Metadata
- DOI
- 10.1093/pm/pnac076
- PMID
- 35587745
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →